Author:
Bonaventura Eleonora,Alberti Luisella,Lucchi Simona,Cappelletti Laura,Fazzone Salvatore,Cattaneo Elisa,Bellini Matteo,Izzo Giana,Parazzini Cecilia,Bosetti Alessandra,Di Profio Elisabetta,Fiore Giulia,Ferrario Matilde,Mameli Chiara,Sangiorgio Arianna,Masnada Silvia,Zuccotti Gian Vincenzo,Veggiotti Pierangelo,Spaccini Luigina,Iascone Maria,Verduci Elvira,Cereda Cristina,Tonduti Davide,
Abstract
IntroductionX-linked adrenoleukodystrophy (X-ALD) is the most common inherited peroxisomal disorder caused by variants in the ABCD1 gene. The main phenotypes observed in men with X-ALD are primary adrenal insufficiency, adrenomyeloneuropathy, and cerebral ALD (cALD). Cerebral ALD consists of a demyelinating progressive cerebral white matter (WM) disease associated with rapid clinical decline and is fatal if left untreated. Hematopoietic stem cell transplantation is the standard treatment for cALD as it stabilizes WM degeneration when performed early in the disease. For this reason, early diagnosis is crucial, and several countries have already implemented their newborn screening programs (NBS) with the assessment of C26:0-lysophosphatidylcholine (C26:0-LPC) values as screening for X-ALD.MethodsIn June 2021, an Italian group in Lombardy launched a pilot study for the implementation of X-ALD in the Italian NBS program. A three-tiered approach was adopted, and it involved quantifying the values of C26:0-LPC and other metabolites in dried blood spots with FIA-MS/MS first, followed by the more specific ultra-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) technique and, finally, the genetic confirmation via focused NGS.DiscussionGenetically confirmed patients are set to undergo a follow-up protocol and are periodically evaluated to promptly start a specific treatment if and when the first signs of brain damage appear, as suggested by international guidelines. A specific disease monitoring protocol has been created based on literature data and personal direct experience.ConclusionThe primary aim of this study was to develop a model able to improve the early diagnosis and subsequent follow-up and timely treatment of X-ALD.EthicsThe study was approved by the local ethics committee. The research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.
Subject
Neurology (clinical),Neurology
Reference48 articles.
1. Newborn screening for X-linked adrenoleukodystrophy;Moser;Int J Neonatal Screen,2016
2. X-linked adrenoleukodystrophy: Very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment;Kemp;Mol Genet Metab,2007
3. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening;Bezman;Ann Neurol.,2001
4. X-linked adrenoleukodystrophy;Moser;Nat Clin Pract Neurol.,2007
5. X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies;Turk;Int J Dev Neurosci.,2020
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献